TMCnet News
International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson's Disease at Neuroscience 2017CARLSBAD, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that its Executive Vice President and Chief Scientific Officer, Russell Kern, PhD will deliver an oral presentation on the company’s first-in-human clinical study in Parkinson's disease at the Society for Neuroscience’s 47th annual meeting, Neuroscience 2017. Session Information
Presentation date: November 12, 2017 Presentation title: Six-Month Update on the First - in - Human Clinical Study of Neural Stem Cells in Patients with Parkinson’s Disease About the Clinical Study The Phase I clinical study is a dose-escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into 12 patients with moderate-to-severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30 million to 70 million neural cells. Following transplantation, the patients will be monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC®. PET scan will be performed at baseline as part of the screening assessment, and at six and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments, such as the Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr, among others. About Parkinson's Disease Parkinson's disease (PD) is a degenerative disorder of the central nervous system, mainly affecting the motor system. The motor symptoms of PD result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related. These symptoms include shaking, rigidity, slowness of movement, and difficulty walking. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, with depression being the most common psychiatric symptom. PD most commonly occurs with people over the age of 50. Currently, medications typically used in the treatment of PD, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to diminish, drugs eventually become ineffective while at the same time, frequently producing a complication marked by involuntar fidgeting movements. In 2013, PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990. About ISC-hpNSC® International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels, following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC® is safe, well-tolerated, and does not cause adverse events such as dyskinesia, systemic toxicity, or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord, and the eye. About International Stem Cell Corporation To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell Safe harbor statement Contacts: International Stem Cell Corporation |